I farmaci antiepilettici nelle metastasi cerebrali: Tollerabilità, efficacia e impatto sull'aspettativa di vita

Translated title of the contribution: Antiepileptic drugs in cerebral metastases: Efficacy, tolerability and impact on life expectancy

B. Jandolo, M. Maschio, L. Dinapoli, S. Gomellini, V. Ferraresi, F. Sperati

Research output: Contribution to journalArticle

Abstract

Aim of the study was to prospectively evaluate efficacy, safety and impact on life expectancy of levetiracetam, oxcarbazepine and topiramate monotherapy in 48 patients with brain metastases. Eighteen patients dropped out, therefore we followed 30 patients. Mean duration of follow up was 6.1 months. At final follow up, 19 patients were seizure-free, while the remaining had a significant reductions of their seizures. There was no difference among each antiepileptic treatment group, we again observed a significant improvement of seizure frequency. Based on Karnofsky Performance Status, age, numbers of cerebral metastases and median of months of survival (7 months) the classification of the total number of our patients can be likened to Class I of prognostic factors of Radiation Therapy Oncology Group (ROTG). There were no significant differences in median survival time between the three groups of patients. The median survival time of our patients treated with levetiracetam, oxcarbazepine and topiramate remained similar to Class I ROTG patients. Our data indicate that levetiracetam, oxcarbazepine and topiramate can be utilized with good tolerability and efficacy over time and without compromising life expectancy in patients with brain metastases, making these antiepileptics a good choice for these patients.

Original languageItalian
Pages (from-to)217-220
Number of pages4
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number140
Publication statusPublished - Apr 2010

Fingerprint

Life Expectancy
Anticonvulsants
etiracetam
Neoplasm Metastasis
Radiation Oncology
Seizures
Survival
Radiotherapy
Karnofsky Performance Status
Brain
Safety

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

I farmaci antiepilettici nelle metastasi cerebrali : Tollerabilità, efficacia e impatto sull'aspettativa di vita. / Jandolo, B.; Maschio, M.; Dinapoli, L.; Gomellini, S.; Ferraresi, V.; Sperati, F.

In: Bollettino - Lega Italiana contro l'Epilessia, No. 140, 04.2010, p. 217-220.

Research output: Contribution to journalArticle

@article{4c50511f0d764e89b12ed0e851e4af28,
title = "I farmaci antiepilettici nelle metastasi cerebrali: Tollerabilit{\`a}, efficacia e impatto sull'aspettativa di vita",
abstract = "Aim of the study was to prospectively evaluate efficacy, safety and impact on life expectancy of levetiracetam, oxcarbazepine and topiramate monotherapy in 48 patients with brain metastases. Eighteen patients dropped out, therefore we followed 30 patients. Mean duration of follow up was 6.1 months. At final follow up, 19 patients were seizure-free, while the remaining had a significant reductions of their seizures. There was no difference among each antiepileptic treatment group, we again observed a significant improvement of seizure frequency. Based on Karnofsky Performance Status, age, numbers of cerebral metastases and median of months of survival (7 months) the classification of the total number of our patients can be likened to Class I of prognostic factors of Radiation Therapy Oncology Group (ROTG). There were no significant differences in median survival time between the three groups of patients. The median survival time of our patients treated with levetiracetam, oxcarbazepine and topiramate remained similar to Class I ROTG patients. Our data indicate that levetiracetam, oxcarbazepine and topiramate can be utilized with good tolerability and efficacy over time and without compromising life expectancy in patients with brain metastases, making these antiepileptics a good choice for these patients.",
keywords = "Brain metastases, Brain tumor-related epilepsy, Levetiracetam, Oxcarbazepine, Topiramate",
author = "B. Jandolo and M. Maschio and L. Dinapoli and S. Gomellini and V. Ferraresi and F. Sperati",
year = "2010",
month = "4",
language = "Italian",
pages = "217--220",
journal = "Bollettino - Lega Italiana contro l'Epilessia",
issn = "0394-560X",
publisher = "Lega Italiana contro l'Epilessia",
number = "140",

}

TY - JOUR

T1 - I farmaci antiepilettici nelle metastasi cerebrali

T2 - Tollerabilità, efficacia e impatto sull'aspettativa di vita

AU - Jandolo, B.

AU - Maschio, M.

AU - Dinapoli, L.

AU - Gomellini, S.

AU - Ferraresi, V.

AU - Sperati, F.

PY - 2010/4

Y1 - 2010/4

N2 - Aim of the study was to prospectively evaluate efficacy, safety and impact on life expectancy of levetiracetam, oxcarbazepine and topiramate monotherapy in 48 patients with brain metastases. Eighteen patients dropped out, therefore we followed 30 patients. Mean duration of follow up was 6.1 months. At final follow up, 19 patients were seizure-free, while the remaining had a significant reductions of their seizures. There was no difference among each antiepileptic treatment group, we again observed a significant improvement of seizure frequency. Based on Karnofsky Performance Status, age, numbers of cerebral metastases and median of months of survival (7 months) the classification of the total number of our patients can be likened to Class I of prognostic factors of Radiation Therapy Oncology Group (ROTG). There were no significant differences in median survival time between the three groups of patients. The median survival time of our patients treated with levetiracetam, oxcarbazepine and topiramate remained similar to Class I ROTG patients. Our data indicate that levetiracetam, oxcarbazepine and topiramate can be utilized with good tolerability and efficacy over time and without compromising life expectancy in patients with brain metastases, making these antiepileptics a good choice for these patients.

AB - Aim of the study was to prospectively evaluate efficacy, safety and impact on life expectancy of levetiracetam, oxcarbazepine and topiramate monotherapy in 48 patients with brain metastases. Eighteen patients dropped out, therefore we followed 30 patients. Mean duration of follow up was 6.1 months. At final follow up, 19 patients were seizure-free, while the remaining had a significant reductions of their seizures. There was no difference among each antiepileptic treatment group, we again observed a significant improvement of seizure frequency. Based on Karnofsky Performance Status, age, numbers of cerebral metastases and median of months of survival (7 months) the classification of the total number of our patients can be likened to Class I of prognostic factors of Radiation Therapy Oncology Group (ROTG). There were no significant differences in median survival time between the three groups of patients. The median survival time of our patients treated with levetiracetam, oxcarbazepine and topiramate remained similar to Class I ROTG patients. Our data indicate that levetiracetam, oxcarbazepine and topiramate can be utilized with good tolerability and efficacy over time and without compromising life expectancy in patients with brain metastases, making these antiepileptics a good choice for these patients.

KW - Brain metastases

KW - Brain tumor-related epilepsy

KW - Levetiracetam

KW - Oxcarbazepine

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=77953114218&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953114218&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:77953114218

SP - 217

EP - 220

JO - Bollettino - Lega Italiana contro l'Epilessia

JF - Bollettino - Lega Italiana contro l'Epilessia

SN - 0394-560X

IS - 140

ER -